Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Cocrystal Pharma, Inc. Director's Dealing 2022

Aug 3, 2022

35066_dirs_2022-08-03_6f0a00ad-11c1-49cc-b79c-6e5936a8eaa3.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cocrystal Pharma, Inc. (COCP)
CIK: 0001412486
Period of Report: 2022-07-25

Reporting Person: Kornberg Roger D. (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2022-07-25 Stock Options (Right to Buy) $0.42 A 280000 Acquired 2032-07-25 Common Stock (280000) Direct

Footnotes

F1: The stock options were issued pursuant to the 2015 Equity Incentive Plan and vest as follows: one-half will vest and become exercisable on July 25, 2023 and the remaining half will vest and become exercisable in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2023, subject to the reporting person continuing to serve as a director of the Company on each applicable vesting date.